Cargando…

Effect of Erythropoiesis-Stimulating Agents on Blood Pressure in Pre-Dialysis Patients

INTRODUCTION: Erythropoiesis-Stimulating Agents (ESA) are hypothesized to increase cardiovascular mortality in patients with chronic kidney disease. One of the proposed mechanisms is the elevation of blood pressure (BP) by ESA. Therefore, we aimed to determine whether the use of ESA was associated w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Suttorp, Marit M., Hoekstra, Tiny, Mittelman, Moshe, Ott, Ilka, Franssen, Casper F. M., Dekker, Friedo W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3877353/ https://www.ncbi.nlm.nih.gov/pubmed/24391978 http://dx.doi.org/10.1371/journal.pone.0084848

Ejemplares similares

Erythropoiesis-stimulating agent resistance and mortality in hemodialysis and peritoneal dialysis patients
por: Suttorp, Marit M, et al.
Publicado: (2013)

Erythropoiesis-stimulating agents and cardiovascular events in patients with myelodysplastic syndrome and multiple myeloma
por: Horváth-Puhó, Erzsébet, et al.
Publicado: (2018)

The influence of Erythropoietin on platelet activation, thrombin generation and FVII/active FVII in patients with AMI
por: Demetz, Gabriele, et al.
Publicado: (2014)

Altitude Pre-Acclimatization with an Erythropoiesis-Stimulating Agent
por: Heldeweg, Micah L. A., et al.
Publicado: (2023)

A meta-analysis of the relative doses of erythropoiesis-stimulating agents in patients undergoing dialysis
por: Bonafont, Xavier, et al.
Publicado: (2009)

Hyporesponsiveness to erythropoiesis-stimulating agent in non-dialysis-dependent CKD patients: The BRIGHTEN study
por: Narita, Ichiei, et al.
Publicado: (2022)

Regional Variation of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Global Daprodustat Dialysis Study (ASCEND-D)
por: Macdougall, Iain C., et al.
Publicado: (2023)

Pharmacovigilance in practice: erythropoiesis-stimulating agents
por: Hedenus, Michael, et al.
Publicado: (2014)

Erythropoiesis stimulating agents: approaches to modulate activity
por: Sinclair, Angus M
Publicado: (2013)

Lower body mass index and mortality in older adults starting dialysis
por: Polinder-Bos, Harmke A., et al.
Publicado: (2018)

Obesity and risk of death or dialysis in younger and older patients on specialized pre-dialysis care
por: Hoogeveen, Ellen K., et al.
Publicado: (2017)

Temporal Trends in Hemoglobin, Use of Erythropoiesis Stimulating Agents, and Major Clinical Outcomes in Incident Dialysis Patients in Canada
por: Canney, Mark, et al.
Publicado: (2021)

Publisher Correction: Lower body mass index and mortality in older adults starting dialysis
por: Polinder-Bos, Harmke A., et al.
Publicado: (2018)

Use of erythropoiesis-stimulating agents in obese hemodialysis patients
por: Park, Sun-Hee
Publicado: (2018)

Treatment of renal anemia: Erythropoiesis stimulating agents and beyond
por: Biggar, Patrick, et al.
Publicado: (2017)

Tips for erythropoiesis-stimulating agent treatment of renal anemia
por: Tomosugi, Naohisa, et al.
Publicado: (2019)

Erythropoiesis-Stimulating Agent Treatment in Patients With COVID-19
por: Fishbane, Steven, et al.
Publicado: (2020)

Dyslipidemia and risk of renal replacement therapy or death in incident pre-dialysis patients
por: Voskamp, Pauline W. M., et al.
Publicado: (2018)

Restricted Use of Erythropoiesis-Stimulating Agent is Safe and Associated with Deferred Dialysis Initiation in Stage 5 Chronic Kidney Disease
por: Pan, Szu-Yu, et al.
Publicado: (2017)

Response to roxadustat in a patient undergoing long-term dialysis and allergic to erythropoiesis-stimulating agents: A case report
por: Xu, Cai, et al.
Publicado: (2022)

No TREATment with Darbepoetin Dosed to Hemoglobin 13 Grams per Deciliter in Type 2 Diabetes with Pre-Dialysis Chronic Kidney Disease - Safety Warnings for Erythropoiesis-Stimulating Agents
por: Curtiss, Frederic R.
Publicado: (2009)

Uric acid: association with rate of renal function decline and time until start of dialysis in incident pre-dialysis patients
por: Nacak, Hakan, et al.
Publicado: (2014)

Lipid Levels and Renal Function Decline in Pre-Dialysis Patients
por: de Goeij, Moniek C.M., et al.
Publicado: (2015)

Association of dialysis facility-level hemoglobin measurement and erythropoiesis-stimulating agent dose adjustment frequencies with dialysis facility-level hemoglobin variation: a retrospective analysis
por: Khan, Irfan, et al.
Publicado: (2011)

A randomized controlled trial evaluating the erythropoiesis stimulating agent sparing potential of a vitamin E-bonded polysulfone dialysis membrane
por: Lines, Simon W., et al.
Publicado: (2014)

Erythropoiesis-stimulating agents: benefits and risks in supportive care of cancer
por: Melosky, B.L.
Publicado: (2008)

Quantitative assessment of minimal effective concentration of erythropoiesis-stimulating agents
por: Yan, X, et al.
Publicado: (2013)

Erythropoiesis stimulating agents and reno-protection: a meta-analysis
por: Elliott, Steve, et al.
Publicado: (2017)

Erythropoiesis-Stimulating Agent Hyporesponsiveness and Adverse Outcomes: Guilty as Charged?
por: Wish, Jay B.
Publicado: (2020)

Inflammation and Erythropoiesis-Stimulating Agent Hyporesponsiveness: A Critical Connection
por: Shah, Hitesh H., et al.
Publicado: (2020)

Selenium Associates With Response to Erythropoiesis-Stimulating Agents in Hemodialysis Patients
por: Yasukawa, Minoru, et al.
Publicado: (2022)

Parathyroidectomy Improves the Consumption of Erythropoiesis-Stimulating Agents in Hemodialysis Patients
por: Lee, Yu-Ting, et al.
Publicado: (2022)

Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer
por: Aapro, M, et al.
Publicado: (2012)

Long- Versus Short-Acting Erythropoiesis-Stimulating Agent Type and Mortality
por: Karaboyas, Angelo, et al.
Publicado: (2020)

Differences in hospitalisation between peritoneal dialysis and haemodialysis patients
por: van Eck van der Sluijs, Anita, et al.
Publicado: (2022)

Associations among Erythroferrone and Biomarkers of Erythropoiesis and Iron Metabolism, and Treatment with Long-Term Erythropoiesis-Stimulating Agents in Patients on Hemodialysis
por: Honda, Hirokazu, et al.
Publicado: (2016)

Course of Symptoms and Health-Related Quality of Life during Specialized Pre-Dialysis Care
por: de Goeij, Moniek C. M., et al.
Publicado: (2014)

Future perspectives on treatment with erythropoiesis-stimulating agents in high-risk patients
por: Anker, Stefan D., et al.
Publicado: (2009)

Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia
por: Pashos, Chris L., et al.
Publicado: (2011)

Neuroimaging in Former Preterm Children Who Received Erythropoiesis Stimulating Agents
por: Phillips, Authors: John, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_21cskht0u61erhcojei06h9gh0